| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 60 | 2021 | 4878 | 3.840 |
Why?
|
| Neoplasms, Glandular and Epithelial | 9 | 2010 | 487 | 1.590 |
Why?
|
| Genes, BRCA1 | 5 | 2011 | 765 | 0.950 |
Why?
|
| Peritoneal Neoplasms | 7 | 2012 | 707 | 0.930 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 22 | 2019 | 11712 | 0.880 |
Why?
|
| Periodicals as Topic | 5 | 2020 | 1469 | 0.870 |
Why?
|
| Fallopian Tube Neoplasms | 5 | 2012 | 328 | 0.850 |
Why?
|
| Platinum | 3 | 2019 | 223 | 0.790 |
Why?
|
| Paclitaxel | 12 | 2011 | 1736 | 0.740 |
Why?
|
| Evaluation Studies as Topic | 2 | 2013 | 1628 | 0.730 |
Why?
|
| Colony-Stimulating Factors | 16 | 1991 | 218 | 0.650 |
Why?
|
| Genes, BRCA2 | 3 | 2011 | 603 | 0.640 |
Why?
|
| Editorial Policies | 2 | 2020 | 457 | 0.620 |
Why?
|
| Genital Neoplasms, Female | 2 | 2019 | 533 | 0.610 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2010 | 326 | 0.600 |
Why?
|
| Medical Oncology | 6 | 2019 | 2313 | 0.560 |
Why?
|
| Organoplatinum Compounds | 6 | 2011 | 410 | 0.550 |
Why?
|
| Clinical Trials as Topic | 3 | 2019 | 8056 | 0.530 |
Why?
|
| Neoplasm Recurrence, Local | 10 | 2019 | 9276 | 0.470 |
Why?
|
| Peritoneum | 4 | 2011 | 224 | 0.450 |
Why?
|
| Antineoplastic Agents, Phytogenic | 4 | 2004 | 626 | 0.450 |
Why?
|
| Taxoids | 4 | 2004 | 669 | 0.440 |
Why?
|
| Cystadenocarcinoma, Serous | 3 | 2007 | 479 | 0.430 |
Why?
|
| Neoplasms | 11 | 2020 | 22072 | 0.430 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2019 | 5253 | 0.420 |
Why?
|
| Antineoplastic Agents | 10 | 2023 | 13630 | 0.410 |
Why?
|
| Carboplatin | 7 | 2023 | 788 | 0.380 |
Why?
|
| Information Dissemination | 1 | 2019 | 1131 | 0.380 |
Why?
|
| Carcinoma | 6 | 2011 | 2331 | 0.370 |
Why?
|
| Growth Substances | 10 | 1990 | 768 | 0.360 |
Why?
|
| Neoplasm Proteins | 6 | 2011 | 3610 | 0.340 |
Why?
|
| Gene Expression Profiling | 6 | 2011 | 9411 | 0.340 |
Why?
|
| Proto-Oncogene Proteins | 7 | 2001 | 4490 | 0.340 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 5 | 1999 | 1407 | 0.340 |
Why?
|
| Informed Consent | 2 | 2007 | 1005 | 0.320 |
Why?
|
| Cystadenocarcinoma, Papillary | 2 | 2001 | 56 | 0.320 |
Why?
|
| Topotecan | 2 | 2007 | 132 | 0.320 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2011 | 376 | 0.310 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2009 | 629 | 0.300 |
Why?
|
| Endometrial Neoplasms | 3 | 2019 | 1357 | 0.300 |
Why?
|
| Tumor Cells, Cultured | 19 | 2000 | 6131 | 0.280 |
Why?
|
| Angiogenesis Inhibitors | 4 | 2012 | 2049 | 0.280 |
Why?
|
| Monocytes | 13 | 1992 | 2575 | 0.270 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 16 | 2000 | 886 | 0.270 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2011 | 3775 | 0.270 |
Why?
|
| Intestinal Perforation | 1 | 2007 | 250 | 0.260 |
Why?
|
| Female | 72 | 2021 | 391270 | 0.250 |
Why?
|
| Microarray Analysis | 1 | 2008 | 747 | 0.250 |
Why?
|
| Apoptosis | 5 | 1999 | 9501 | 0.250 |
Why?
|
| Antibodies, Monoclonal | 14 | 2019 | 9185 | 0.250 |
Why?
|
| Humans | 112 | 2023 | 760621 | 0.250 |
Why?
|
| Treatment Outcome | 14 | 2019 | 65017 | 0.240 |
Why?
|
| Granulocytes | 7 | 1988 | 551 | 0.240 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2011 | 8515 | 0.240 |
Why?
|
| Drug Administration Schedule | 9 | 2019 | 4899 | 0.240 |
Why?
|
| Cisplatin | 4 | 2011 | 1644 | 0.230 |
Why?
|
| Receptors, Lymphocyte Homing | 2 | 1995 | 141 | 0.230 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2011 | 2873 | 0.230 |
Why?
|
| Publishing | 1 | 2011 | 836 | 0.230 |
Why?
|
| Hematopoietic Stem Cells | 12 | 1992 | 3387 | 0.230 |
Why?
|
| Deoxycytidine | 2 | 2010 | 873 | 0.220 |
Why?
|
| Germ-Line Mutation | 3 | 2019 | 1841 | 0.210 |
Why?
|
| Mullerian Ducts | 1 | 2003 | 201 | 0.200 |
Why?
|
| Granulosa Cell Tumor | 1 | 2003 | 72 | 0.200 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3085 | 0.200 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3205 | 0.200 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 5325 | 0.200 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 1993 | 685 | 0.200 |
Why?
|
| Patient Advocacy | 1 | 2004 | 358 | 0.200 |
Why?
|
| Leukemia, Myeloid | 5 | 1991 | 695 | 0.190 |
Why?
|
| Oncogenes | 3 | 2019 | 1220 | 0.190 |
Why?
|
| Endpoint Determination | 1 | 2004 | 597 | 0.190 |
Why?
|
| Cell Adhesion | 7 | 1999 | 3094 | 0.190 |
Why?
|
| Gynecology | 1 | 2007 | 528 | 0.190 |
Why?
|
| Cytarabine | 3 | 1993 | 696 | 0.180 |
Why?
|
| Receptors, Cell Surface | 5 | 1995 | 2825 | 0.180 |
Why?
|
| Prognosis | 13 | 2020 | 29658 | 0.180 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2001 | 155 | 0.180 |
Why?
|
| bcl-2-Associated X Protein | 5 | 1999 | 282 | 0.170 |
Why?
|
| Combined Modality Therapy | 6 | 2019 | 8552 | 0.170 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2004 | 861 | 0.170 |
Why?
|
| Adenocarcinoma, Clear Cell | 3 | 2011 | 217 | 0.170 |
Why?
|
| Glycoproteins | 3 | 2003 | 2208 | 0.170 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2019 | 17790 | 0.170 |
Why?
|
| Maximum Tolerated Dose | 3 | 2010 | 877 | 0.160 |
Why?
|
| Dermatomyositis | 1 | 2001 | 256 | 0.160 |
Why?
|
| Infusions, Parenteral | 3 | 2011 | 399 | 0.140 |
Why?
|
| Histocompatibility Antigens Class II | 3 | 1986 | 1446 | 0.140 |
Why?
|
| Research Design | 3 | 2009 | 6180 | 0.140 |
Why?
|
| Epithelium | 6 | 1999 | 1605 | 0.140 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 1997 | 2919 | 0.130 |
Why?
|
| DNA Mismatch Repair | 1 | 2019 | 429 | 0.130 |
Why?
|
| Integrins | 3 | 1995 | 839 | 0.130 |
Why?
|
| Receptors, Cytoadhesin | 1 | 1995 | 8 | 0.130 |
Why?
|
| Phthalazines | 1 | 2018 | 383 | 0.130 |
Why?
|
| Tumor Stem Cell Assay | 3 | 1991 | 115 | 0.130 |
Why?
|
| Cell Adhesion Molecules | 4 | 1994 | 1602 | 0.130 |
Why?
|
| Neoplasm Staging | 8 | 2011 | 11152 | 0.130 |
Why?
|
| Biopsy | 1 | 2007 | 6771 | 0.120 |
Why?
|
| Disease-Free Survival | 5 | 2010 | 6828 | 0.120 |
Why?
|
| Drug Interactions | 2 | 2010 | 1428 | 0.120 |
Why?
|
| Survival Analysis | 8 | 2019 | 10182 | 0.120 |
Why?
|
| Mutation | 4 | 2018 | 29932 | 0.120 |
Why?
|
| Carrier Proteins | 3 | 1998 | 4938 | 0.120 |
Why?
|
| Rectum | 1 | 2019 | 895 | 0.120 |
Why?
|
| Platinum Compounds | 2 | 2010 | 95 | 0.110 |
Why?
|
| Evidence-Based Medicine | 2 | 2020 | 3696 | 0.110 |
Why?
|
| Oligopeptides | 3 | 1995 | 1187 | 0.110 |
Why?
|
| Indium Radioisotopes | 1 | 1993 | 113 | 0.110 |
Why?
|
| Biological Products | 1 | 2003 | 916 | 0.110 |
Why?
|
| RNA, Neoplasm | 2 | 2008 | 749 | 0.110 |
Why?
|
| Pentetic Acid | 1 | 1993 | 209 | 0.110 |
Why?
|
| Middle Aged | 26 | 2019 | 220352 | 0.110 |
Why?
|
| Hysterectomy | 1 | 2019 | 904 | 0.110 |
Why?
|
| Growth Inhibitors | 2 | 2003 | 378 | 0.110 |
Why?
|
| Interleukin-3 | 5 | 1991 | 425 | 0.100 |
Why?
|
| Signal Transduction | 6 | 2011 | 23376 | 0.100 |
Why?
|
| DNA, Neoplasm | 3 | 2011 | 1745 | 0.100 |
Why?
|
| Patient Selection | 1 | 2004 | 4283 | 0.100 |
Why?
|
| Ovary | 3 | 2004 | 958 | 0.100 |
Why?
|
| Leukemia, Myeloid, Acute | 5 | 1991 | 3602 | 0.100 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 1447 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2009 | 10344 | 0.100 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2004 | 3529 | 0.090 |
Why?
|
| Interferon-gamma | 7 | 1989 | 3157 | 0.090 |
Why?
|
| Erythroid Precursor Cells | 1 | 1992 | 211 | 0.090 |
Why?
|
| Antigens, Neoplasm | 1 | 1999 | 1998 | 0.090 |
Why?
|
| Injections, Intraperitoneal | 2 | 2003 | 412 | 0.090 |
Why?
|
| Exonucleases | 1 | 2010 | 47 | 0.090 |
Why?
|
| Ethics, Medical | 2 | 2007 | 783 | 0.090 |
Why?
|
| Bone Marrow | 6 | 1993 | 2912 | 0.090 |
Why?
|
| Transfection | 5 | 1998 | 5781 | 0.090 |
Why?
|
| Aged | 20 | 2019 | 169152 | 0.090 |
Why?
|
| Dioxoles | 1 | 2010 | 95 | 0.090 |
Why?
|
| Interleukin-1 | 3 | 1989 | 1249 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2011 | 6544 | 0.090 |
Why?
|
| Tetrahydroisoquinolines | 1 | 2010 | 81 | 0.090 |
Why?
|
| Genetic Association Studies | 1 | 2019 | 2717 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2009 | 10827 | 0.090 |
Why?
|
| Radionuclide Imaging | 1 | 1993 | 1975 | 0.080 |
Why?
|
| Bone Marrow Cells | 4 | 1992 | 2414 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 3 | 2005 | 1705 | 0.080 |
Why?
|
| Research | 1 | 1997 | 1974 | 0.080 |
Why?
|
| Immunohistochemistry | 6 | 2004 | 11071 | 0.080 |
Why?
|
| Blast Crisis | 1 | 1989 | 101 | 0.080 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2003 | 2003 | 0.080 |
Why?
|
| Disease Management | 1 | 2019 | 2514 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 1988 | 4357 | 0.080 |
Why?
|
| DNA, Complementary | 2 | 2004 | 1991 | 0.080 |
Why?
|
| Risk Factors | 9 | 2020 | 74359 | 0.080 |
Why?
|
| Adult | 21 | 2019 | 219994 | 0.080 |
Why?
|
| Collagen | 3 | 1995 | 2636 | 0.080 |
Why?
|
| Cell Division | 7 | 1997 | 4463 | 0.080 |
Why?
|
| Neoplastic Stem Cells | 2 | 1998 | 1347 | 0.080 |
Why?
|
| Kidney | 1 | 2023 | 7064 | 0.080 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 1990 | 431 | 0.070 |
Why?
|
| Receptors, Fibronectin | 2 | 1999 | 37 | 0.070 |
Why?
|
| Piperazines | 1 | 2018 | 2525 | 0.070 |
Why?
|
| Recombinant Proteins | 9 | 1996 | 6538 | 0.070 |
Why?
|
| Benzenesulfonates | 1 | 2008 | 165 | 0.070 |
Why?
|
| Receptors, Estrogen | 1 | 1996 | 2210 | 0.070 |
Why?
|
| Immunotherapy | 1 | 2003 | 4642 | 0.070 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2011 | 618 | 0.070 |
Why?
|
| Mass Screening | 1 | 2003 | 5423 | 0.070 |
Why?
|
| Somatomedins | 1 | 2007 | 178 | 0.070 |
Why?
|
| Etoposide | 2 | 2000 | 630 | 0.070 |
Why?
|
| Histiocytes | 1 | 1987 | 98 | 0.070 |
Why?
|
| Health Status | 1 | 2020 | 4081 | 0.070 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2010 | 640 | 0.070 |
Why?
|
| Carcinosarcoma | 1 | 2007 | 104 | 0.070 |
Why?
|
| Genetic Testing | 1 | 2019 | 3531 | 0.070 |
Why?
|
| Niacinamide | 1 | 2008 | 414 | 0.070 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2009 | 666 | 0.070 |
Why?
|
| Alprostadil | 1 | 1986 | 86 | 0.070 |
Why?
|
| Remission Induction | 2 | 2007 | 2392 | 0.070 |
Why?
|
| Fluorouracil | 1 | 2010 | 1631 | 0.060 |
Why?
|
| bcl-X Protein | 2 | 1997 | 413 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 2 | 2011 | 4713 | 0.060 |
Why?
|
| Phenylurea Compounds | 1 | 2008 | 529 | 0.060 |
Why?
|
| Clone Cells | 4 | 1998 | 1660 | 0.060 |
Why?
|
| Colony-Forming Units Assay | 1 | 1985 | 351 | 0.060 |
Why?
|
| Immunoblotting | 3 | 1997 | 1649 | 0.060 |
Why?
|
| Polyethylene Glycols | 1 | 2010 | 1189 | 0.060 |
Why?
|
| DNA Mutational Analysis | 2 | 2011 | 4107 | 0.060 |
Why?
|
| Tetradecanoylphorbol Acetate | 3 | 1991 | 818 | 0.060 |
Why?
|
| Neoplasm Transplantation | 2 | 1999 | 2014 | 0.060 |
Why?
|
| Neutrophils | 4 | 1992 | 3767 | 0.060 |
Why?
|
| Cell Line, Tumor | 2 | 2011 | 16939 | 0.060 |
Why?
|
| Adenocarcinoma | 3 | 2001 | 6315 | 0.060 |
Why?
|
| Databases, Genetic | 1 | 2011 | 1738 | 0.060 |
Why?
|
| Risk Assessment | 3 | 2020 | 24123 | 0.060 |
Why?
|
| Postoperative Care | 2 | 2004 | 1479 | 0.060 |
Why?
|
| Receptors, Colony-Stimulating Factor | 4 | 1990 | 50 | 0.060 |
Why?
|
| Genomics | 1 | 2019 | 5794 | 0.060 |
Why?
|
| Doxorubicin | 1 | 2010 | 2209 | 0.050 |
Why?
|
| Mice, Nude | 3 | 1999 | 3607 | 0.050 |
Why?
|
| Climacteric | 1 | 2003 | 57 | 0.050 |
Why?
|
| Sirolimus | 1 | 2010 | 1547 | 0.050 |
Why?
|
| Epithelial Cells | 3 | 2003 | 3663 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2010 | 5643 | 0.050 |
Why?
|
| Quinazolines | 1 | 2009 | 1363 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2007 | 5201 | 0.050 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2000 | 1351 | 0.050 |
Why?
|
| Administration, Oral | 2 | 2009 | 4035 | 0.050 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2005 | 276 | 0.050 |
Why?
|
| Testicular Hormones | 1 | 2003 | 188 | 0.050 |
Why?
|
| RNA Interference | 1 | 2011 | 2846 | 0.050 |
Why?
|
| Inhibins | 1 | 2003 | 209 | 0.050 |
Why?
|
| CA-125 Antigen | 1 | 2004 | 279 | 0.050 |
Why?
|
| Ovariectomy | 1 | 2004 | 611 | 0.050 |
Why?
|
| Specimen Handling | 1 | 2007 | 707 | 0.050 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 1991 | 114 | 0.050 |
Why?
|
| Back | 1 | 2001 | 64 | 0.050 |
Why?
|
| RNA, Small Interfering | 1 | 2011 | 3442 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 2 | 1988 | 1827 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 3 | 1999 | 3735 | 0.050 |
Why?
|
| SEER Program | 1 | 2007 | 1530 | 0.050 |
Why?
|
| Forehead | 1 | 2001 | 74 | 0.050 |
Why?
|
| Philadelphia Chromosome | 2 | 1993 | 117 | 0.050 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2010 | 2058 | 0.050 |
Why?
|
| Quality of Life | 2 | 2018 | 13308 | 0.050 |
Why?
|
| Drugs, Investigational | 1 | 2003 | 214 | 0.050 |
Why?
|
| RNA, Messenger | 7 | 1998 | 12766 | 0.050 |
Why?
|
| Aged, 80 and over | 5 | 2011 | 58995 | 0.050 |
Why?
|
| Anti-Mullerian Hormone | 1 | 2003 | 407 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1996 | 4024 | 0.040 |
Why?
|
| Survival Rate | 2 | 2005 | 12808 | 0.040 |
Why?
|
| Receptors, Interleukin-2 | 4 | 1989 | 562 | 0.040 |
Why?
|
| Cell Line | 9 | 1996 | 15620 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 8624 | 0.040 |
Why?
|
| HLA-DR Antigens | 3 | 1986 | 630 | 0.040 |
Why?
|
| Recurrence | 1 | 2012 | 8482 | 0.040 |
Why?
|
| Molecular Sequence Data | 5 | 1996 | 17624 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 1630 | 0.040 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2001 | 412 | 0.040 |
Why?
|
| Cyclin D1 | 1 | 2001 | 451 | 0.040 |
Why?
|
| Lac Operon | 1 | 1999 | 237 | 0.040 |
Why?
|
| Laparoscopy | 1 | 2011 | 2147 | 0.040 |
Why?
|
| T-Lymphocytes | 3 | 1994 | 10181 | 0.040 |
Why?
|
| bcl-Associated Death Protein | 1 | 1998 | 102 | 0.040 |
Why?
|
| Chromosomal Instability | 1 | 2019 | 177 | 0.040 |
Why?
|
| Thorax | 1 | 2001 | 553 | 0.040 |
Why?
|
| Antigens, CD | 3 | 1995 | 4000 | 0.040 |
Why?
|
| Ascitic Fluid | 1 | 1998 | 189 | 0.040 |
Why?
|
| Interphase | 3 | 1989 | 228 | 0.040 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 1998 | 105 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 3 | 2001 | 6068 | 0.040 |
Why?
|
| Verapamil | 1 | 1998 | 242 | 0.040 |
Why?
|
| beta-Galactosidase | 1 | 1999 | 575 | 0.040 |
Why?
|
| Isoantigens | 1 | 2000 | 552 | 0.040 |
Why?
|
| Extracellular Matrix Proteins | 2 | 1992 | 829 | 0.040 |
Why?
|
| Patient Participation | 1 | 2007 | 1439 | 0.040 |
Why?
|
| Interleukin-2 | 4 | 1989 | 1889 | 0.040 |
Why?
|
| Phosphorylation | 5 | 2001 | 8313 | 0.040 |
Why?
|
| Stem Cells | 2 | 1993 | 3523 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2003 | 1791 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2004 | 15289 | 0.040 |
Why?
|
| Adenoviruses, Human | 1 | 1999 | 255 | 0.040 |
Why?
|
| Kinetics | 3 | 1996 | 6377 | 0.040 |
Why?
|
| Receptors, Immunologic | 3 | 1990 | 1411 | 0.040 |
Why?
|
| Vinblastine | 1 | 1998 | 487 | 0.040 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2001 | 854 | 0.030 |
Why?
|
| Laminin | 2 | 1995 | 405 | 0.030 |
Why?
|
| Laparotomy | 1 | 1999 | 465 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 12531 | 0.030 |
Why?
|
| Pyridines | 1 | 2008 | 2879 | 0.030 |
Why?
|
| Neutropenia | 2 | 2000 | 884 | 0.030 |
Why?
|
| Cyclophosphamide | 2 | 2000 | 2221 | 0.030 |
Why?
|
| Tyrosine | 2 | 1991 | 1438 | 0.030 |
Why?
|
| G1 Phase | 1 | 1997 | 403 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2001 | 1135 | 0.030 |
Why?
|
| Estradiol | 1 | 2003 | 1932 | 0.030 |
Why?
|
| Muscle Proteins | 1 | 2001 | 1152 | 0.030 |
Why?
|
| Receptors, Vitronectin | 1 | 1995 | 47 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2019 | 1754 | 0.030 |
Why?
|
| Hydroxyurea | 1 | 1996 | 282 | 0.030 |
Why?
|
| Diaphragm | 1 | 1997 | 351 | 0.030 |
Why?
|
| Peritoneal Cavity | 1 | 1995 | 138 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 1987 | 4433 | 0.030 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 1998 | 563 | 0.030 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 1997 | 345 | 0.030 |
Why?
|
| Endotoxins | 2 | 1988 | 521 | 0.030 |
Why?
|
| Amino Acid Sequence | 4 | 1996 | 13451 | 0.030 |
Why?
|
| Genetic Variation | 2 | 2019 | 6551 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 1999 | 1529 | 0.030 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 2 | 1992 | 48 | 0.030 |
Why?
|
| Radiation Tolerance | 1 | 1997 | 480 | 0.030 |
Why?
|
| Fibronectins | 2 | 1995 | 722 | 0.030 |
Why?
|
| Vincristine | 1 | 1996 | 1039 | 0.030 |
Why?
|
| Leukocyte Count | 4 | 1991 | 1600 | 0.030 |
Why?
|
| Cell Separation | 4 | 1990 | 1720 | 0.030 |
Why?
|
| Transcription, Genetic | 4 | 1995 | 7593 | 0.030 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 1993 | 136 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 1991 | 2418 | 0.030 |
Why?
|
| Hematopoiesis | 3 | 1988 | 2050 | 0.030 |
Why?
|
| Vaginal Smears | 1 | 1996 | 495 | 0.030 |
Why?
|
| United States | 3 | 2019 | 72461 | 0.030 |
Why?
|
| Gene Expression Regulation | 3 | 1987 | 11903 | 0.030 |
Why?
|
| Cytogenetics | 1 | 1993 | 198 | 0.030 |
Why?
|
| Antigens, Surface | 2 | 1988 | 1608 | 0.030 |
Why?
|
| Mice | 7 | 1999 | 81208 | 0.030 |
Why?
|
| DNA-Binding Proteins | 2 | 2001 | 9585 | 0.030 |
Why?
|
| Infusion Pumps | 1 | 1993 | 163 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2003 | 2608 | 0.030 |
Why?
|
| Binding, Competitive | 2 | 1991 | 1142 | 0.030 |
Why?
|
| Transplantation, Heterologous | 2 | 1998 | 2379 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2000 | 1174 | 0.030 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 1994 | 691 | 0.020 |
Why?
|
| Cations, Divalent | 1 | 1992 | 168 | 0.020 |
Why?
|
| Microbial Collagenase | 1 | 1992 | 113 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 1996 | 1089 | 0.020 |
Why?
|
| Bone Marrow Diseases | 1 | 1993 | 232 | 0.020 |
Why?
|
| Tamoxifen | 1 | 1996 | 963 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2001 | 2802 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2001 | 4291 | 0.020 |
Why?
|
| Cell Communication | 2 | 1990 | 1653 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 1994 | 1126 | 0.020 |
Why?
|
| Models, Genetic | 2 | 2011 | 3442 | 0.020 |
Why?
|
| Cell Survival | 2 | 1998 | 5797 | 0.020 |
Why?
|
| Decision Making | 1 | 2004 | 3925 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 1995 | 1697 | 0.020 |
Why?
|
| Cell Differentiation | 5 | 1990 | 11481 | 0.020 |
Why?
|
| Cells, Cultured | 6 | 1989 | 18957 | 0.020 |
Why?
|
| Papillomaviridae | 1 | 1996 | 1117 | 0.020 |
Why?
|
| Hyaluronic Acid | 1 | 1993 | 482 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 3 | 1996 | 2471 | 0.020 |
Why?
|
| S Phase | 1 | 1991 | 422 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 1991 | 641 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 1999 | 3380 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 14660 | 0.020 |
Why?
|
| Culture Media | 2 | 1990 | 900 | 0.020 |
Why?
|
| Transcription Factors | 2 | 2001 | 12103 | 0.020 |
Why?
|
| Genes, Neoplasm | 1 | 2011 | 370 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2000 | 2725 | 0.020 |
Why?
|
| DNA Repair | 1 | 1998 | 2039 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 1990 | 346 | 0.020 |
Why?
|
| Catheters, Indwelling | 1 | 2011 | 428 | 0.020 |
Why?
|
| Acute Disease | 2 | 1991 | 7269 | 0.020 |
Why?
|
| Animals | 9 | 1999 | 167963 | 0.020 |
Why?
|
| Cell Cycle | 1 | 1996 | 2934 | 0.020 |
Why?
|
| Drug Resistance | 1 | 1994 | 1617 | 0.020 |
Why?
|
| Antibodies | 1 | 1996 | 2421 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1990 | 534 | 0.020 |
Why?
|
| Lymphocyte Activation | 2 | 2000 | 5496 | 0.020 |
Why?
|
| Leukopenia | 1 | 1988 | 211 | 0.020 |
Why?
|
| Blood Cells | 1 | 1990 | 305 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 1999 | 5785 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 1995 | 1726 | 0.020 |
Why?
|
| Age Factors | 2 | 2003 | 18416 | 0.020 |
Why?
|
| Cross-Linking Reagents | 1 | 1990 | 685 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 1996 | 2907 | 0.020 |
Why?
|
| Palliative Care | 1 | 2002 | 3607 | 0.020 |
Why?
|
| Complement System Proteins | 1 | 1990 | 782 | 0.020 |
Why?
|
| GTP-Binding Proteins | 1 | 1991 | 951 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2001 | 12965 | 0.020 |
Why?
|
| Suspensions | 1 | 1986 | 66 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 1991 | 2234 | 0.020 |
Why?
|
| Rosette Formation | 1 | 1985 | 152 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2011 | 12159 | 0.020 |
Why?
|
| Endocytosis | 1 | 1990 | 959 | 0.020 |
Why?
|
| Antigens, Differentiation | 1 | 1988 | 911 | 0.020 |
Why?
|
| Male | 8 | 2011 | 359744 | 0.020 |
Why?
|
| Gene Rearrangement | 1 | 1990 | 1122 | 0.020 |
Why?
|
| Disease Progression | 1 | 2001 | 13502 | 0.010 |
Why?
|
| Incidence | 1 | 2003 | 21392 | 0.010 |
Why?
|
| Base Sequence | 1 | 1995 | 12446 | 0.010 |
Why?
|
| Multigene Family | 1 | 2007 | 1077 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1991 | 3804 | 0.010 |
Why?
|
| Genes | 1 | 1987 | 1845 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1991 | 1974 | 0.010 |
Why?
|
| Lymphokines | 1 | 1985 | 927 | 0.010 |
Why?
|
| Reference Values | 1 | 1990 | 4925 | 0.010 |
Why?
|
| Down-Regulation | 1 | 1990 | 2913 | 0.010 |
Why?
|
| Protein Binding | 1 | 1994 | 9335 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 2007 | 2381 | 0.010 |
Why?
|
| Macrophages | 2 | 1987 | 5745 | 0.010 |
Why?
|
| Vanadates | 2 | 1991 | 82 | 0.010 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1990 | 1547 | 0.010 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2000 | 321 | 0.010 |
Why?
|
| Breast Neoplasms | 2 | 1999 | 21025 | 0.010 |
Why?
|
| Cell Fusion | 1 | 2000 | 293 | 0.010 |
Why?
|
| Penetrance | 1 | 2001 | 388 | 0.010 |
Why?
|
| Cytokines | 2 | 1991 | 7343 | 0.010 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 1990 | 1628 | 0.010 |
Why?
|
| Loss of Heterozygosity | 1 | 2001 | 659 | 0.010 |
Why?
|
| MutS Homolog 2 Protein | 1 | 1998 | 195 | 0.010 |
Why?
|
| Genome, Human | 1 | 2011 | 4417 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 1997 | 5799 | 0.010 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 1987 | 1403 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2001 | 1055 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2019 | 41335 | 0.010 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2000 | 824 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2000 | 1342 | 0.010 |
Why?
|
| Histocytological Preparation Techniques | 1 | 1996 | 33 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 1999 | 11345 | 0.010 |
Why?
|
| CHO Cells | 1 | 1998 | 1389 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 1998 | 835 | 0.010 |
Why?
|
| Escherichia coli | 1 | 1988 | 4219 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2000 | 1871 | 0.010 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2001 | 1115 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 1993 | 5649 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2011 | 80372 | 0.010 |
Why?
|
| Models, Biological | 2 | 2007 | 9467 | 0.010 |
Why?
|
| Cricetinae | 1 | 1998 | 2427 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 1999 | 13262 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2001 | 3615 | 0.010 |
Why?
|
| Leukapheresis | 1 | 1993 | 134 | 0.010 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2000 | 1765 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 1998 | 2057 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 20080 | 0.010 |
Why?
|
| Genetic Engineering | 1 | 1998 | 933 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2001 | 2448 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 1989 | 7850 | 0.010 |
Why?
|
| Cytoplasm | 1 | 1996 | 1516 | 0.010 |
Why?
|
| Receptors, Interleukin-3 | 1 | 1990 | 29 | 0.010 |
Why?
|
| Thymidine | 1 | 1991 | 299 | 0.010 |
Why?
|
| Alleles | 1 | 2001 | 6898 | 0.010 |
Why?
|
| BRCA1 Protein | 1 | 1996 | 1147 | 0.010 |
Why?
|
| Biological Factors | 1 | 1990 | 157 | 0.010 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 1991 | 330 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 1991 | 459 | 0.000 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1998 | 2828 | 0.000 |
Why?
|
| Cryopreservation | 1 | 1993 | 717 | 0.000 |
Why?
|
| Bone Marrow Examination | 1 | 1988 | 155 | 0.000 |
Why?
|
| Precipitin Tests | 1 | 1989 | 814 | 0.000 |
Why?
|
| Erythrocyte Count | 1 | 1988 | 157 | 0.000 |
Why?
|
| Methods | 1 | 1988 | 1074 | 0.000 |
Why?
|
| Erythroblasts | 1 | 1988 | 143 | 0.000 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 1998 | 2895 | 0.000 |
Why?
|
| Macrophage-1 Antigen | 1 | 1988 | 286 | 0.000 |
Why?
|
| Blotting, Northern | 1 | 1989 | 1543 | 0.000 |
Why?
|
| Adolescent | 3 | 2009 | 87810 | 0.000 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1988 | 1304 | 0.000 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1989 | 1744 | 0.000 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2001 | 3218 | 0.000 |
Why?
|
| Platelet Count | 1 | 1988 | 777 | 0.000 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 1988 | 629 | 0.000 |
Why?
|
| Iodine Radioisotopes | 1 | 1989 | 1032 | 0.000 |
Why?
|
| Kidney Neoplasms | 1 | 2001 | 4312 | 0.000 |
Why?
|
| Epitopes | 1 | 1991 | 2503 | 0.000 |
Why?
|
| DNA Replication | 1 | 1991 | 1412 | 0.000 |
Why?
|
| Nuclear Proteins | 1 | 1998 | 5791 | 0.000 |
Why?
|
| Rabbits | 1 | 1990 | 4773 | 0.000 |
Why?
|
| Adjuvants, Immunologic | 1 | 1989 | 1039 | 0.000 |
Why?
|
| Transplantation, Autologous | 1 | 1988 | 2116 | 0.000 |
Why?
|
| Protein Conformation | 1 | 1991 | 3969 | 0.000 |
Why?
|
| Ambulatory Care | 1 | 1993 | 2781 | 0.000 |
Why?
|
| Leukemia | 1 | 1990 | 1520 | 0.000 |
Why?
|
| Lipopolysaccharides | 1 | 1989 | 2209 | 0.000 |
Why?
|
| Fever | 1 | 1988 | 1617 | 0.000 |
Why?
|
| Lymphoma | 1 | 1990 | 1898 | 0.000 |
Why?
|
| Peptides | 1 | 1991 | 4354 | 0.000 |
Why?
|
| Drug Therapy, Combination | 1 | 1988 | 6498 | 0.000 |
Why?
|
| Time Factors | 2 | 1990 | 40165 | 0.000 |
Why?
|
| Sarcoma | 1 | 1988 | 1786 | 0.000 |
Why?
|
| Multiple Myeloma | 1 | 1992 | 5130 | 0.000 |
Why?
|
| Phenotype | 1 | 1990 | 16546 | 0.000 |
Why?
|
| Proteins | 1 | 1986 | 6029 | 0.000 |
Why?
|